NEWS
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
Coya Therapeutics (NASDAQ: COYA) announced the acceptance of a peer-reviewed manuscript in Frontiers in Neurology. The study, titled 'A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,' highlights the halting of ALS progression at six months. The therapy also showed reduced inflammation and oxidative stress, and enhanced Regulatory T cell (Treg) function. This data was previously presented at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference. Dr. Fred Grossman, Coya's Chief Medical Officer, sees this as significant validation for their approach.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2791Followers
108Following
29KVisitors
Follow